Who is Orforglipron suitable for?
Orforglipron has been studied and approved for weight management in adults with obesity, or with overweight in combination with at least one weight-related condition. The precise indication criteria (including BMI limits) and the assessment of whether the drug is suitable for your situation can be found on the Foundayo page.
The definitive indication will follow after approval by the health authorities.
How Orforglipron works
Orforglipron acts as a GLP-1 receptor agonist: it mimics the body's own GLP-1 hormone. This hormone plays a role in:
- Regulation of blood sugar levels
- Reduction of appetite
- Delayed gastric emptying
For a complete overview of the effects on weight loss and blood sugar, and the dosage build-up schedule, please refer to the Foundayo page, where the mechanism of action is described based on the approved product information.
Orforglipron approval status
Orforglipron has been approved by the American FDA (April 2026) and the British MHRA (August 2026) under the brand name Foundayo®. In the European Union and the Netherlands, the drug is not yet registered; a European introduction is expected no earlier than 2027.
Once a medicine is approved, its safety and effectiveness are substantiated by extensive clinical studies (including the ATTAIN research program). Complete safety information, side effects, and contraindications can be found on the Foundayo page.
The difference between Orforglipron and other GLP-1 medications
An important distinction of Orforglipron compared to existing treatments is the administration method.
- Orforglipron → tablet (oral), at any time of day, with or without food
- Many other GLP-1 drugs → injection, or tablet with strict fasted intake
In addition:
Orforglipron works exclusively on the GLP-1 receptor
Some other drugs (such as dual or triple agonists, e.g., retatrutide) act on multiple receptors simultaneously
Orforglipron reimbursement by health insurer
Because Orforglipron has not yet been approved:
- reimbursement is currently not possible
- it is still unknown whether it will be reimbursed in the future
This depends on:
- effectiveness
- cost price
- national guidelines
Orforglipron Dosage
Orforglipron is available in multiple strengths, with a titration schedule that maintains a minimum of 30 days per step. The exact dosage schedule and available strengths can be found on the Foundayo page, based on the approved product information.
When will Orforglipron be released?
Orforglipron is already on the market in the United States and the United Kingdom, under the brand name Foundayo®. In the Netherlands and the rest of the EU, the drug is not yet registered. As soon as this changes, you will find the current status, price, and availability on our Foundayo page.
Summary
- Orforglipron is the active ingredient in Foundayo®, developed by Eli Lilly
- It is an orally administered GLP-1 receptor agonist — a unique advantage within this class of medicines
- Approved in the US (April 2026) and UK (August 2026)
- Not yet registered in the Netherlands/EU
- For price, availability, dosage, and side effects: see the Foundayo page
